ClinicalTrials.gg
TerminatedNCT03062007Updated Jul 16, 2019

Open-label Study of Safety, Tolerability and Pharmacokinetics of Multiple Doses of BI-CON-02 in Patients With HER2-positive Metastatic Breast Cancer, Previously Treated With Trastuzumab

A Phase 1 interventional study of BI-CON-02 in Metastatic Breast Cancer, sponsored by Biointegrator LLC. Terminated at 6 sites in Russian Federation. Open to female participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2019-07-16.

Sponsored by Biointegrator LLC · Phase 1, Interventional, and Treatment

How we know · 4 judgments

Why this study was terminated
Sponsor's decision

From the registry’s dates

  • Registered 5 months after the study started (first participant enrolled Sep 2016, registered Feb 2017).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
6
Allocation
Not applicable
Ages
18 Years and older
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 180 studies in Breast Neoplasms with a site in Russian Federation — 9 open to participants now, 10 under way, 1 of them phase 3. Breast Neoplasms · Russian Federation.

Enrollment
164th of 166
6 · median 334
Started
2016
with 3 others
Phase 1
7 of 180
1 open now
Registered
138th of 180
by date

Among the 180 studies in Breast Neoplasms with a site in Russian Federation, this one is the 164th largest by enrollment of the 166 interventional ones that give a count, is one of 4 that started in 2016, is one of 7 in phase 1, and was the 138th registered.

Breast Neoplasms

14,855 studies on the registry are indexed under Breast Neoplasms; 3,321 are open to participants now.

Browse Breast Neoplasms studies →

Open to participants now

9 of the 180 studies in Breast Neoplasms with a site in Russian Federation are open now. Recruiting first, the newest first:

4 more — sign in →

All 9 open studies →

A study can be open while its sites in Russian Federation have not opened yet or have stopped. Only those recruiting at a site in Russian Federation →

Who these studies take

Of the 2,403 Breast Neoplasms studies recruiting now, 1,574 (66%) set no upper age limit and 591 (25%) stop at 75 or younger; 103 take children under 18; 215 take healthy volunteers.

This study: 18 Years and older · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 180 studies in Breast Neoplasms with a site in Russian Federation, or all of them as a file.
02

Study summary

This study will evaluate the safety and tolerability of BI-CON-02 in patients with HER2-positive metastatic breast cancer, previously treated with trastuzumab The clinical trial protocol for BI-CON-02 prescribes a start dose of 0,3 mg/kg. After the Data and Safety Monitoring Committee evaluates the data of tolerability and safety of BI-CON-02, received during 3 weeks of investigational product therapy (Week 3, Day 1) and approves, extra doses can be used.

Once the safety of investigational product is confirmed, the dose will be increased in the subsequent cohorts. Planned doses - 0,3 mg/kg; 0,6 mg/kg; 1,2 mg/kg; 2,4 mg/kg; 3,6 mg/kg and 4,8 mg/kg.

03

Conditions studied

  • Metastatic Breast Cancer

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

To participate in the clinical study, patients must comply to the following criteria:

  1. Signed patient's information sheet and form to participate in the study
  2. Females aged ≥ 18 years
  3. confirmed diagnosis of locally advanced or breast cancer.
  4. -positive tumor status by results of immunohistochemistry (IHC3+) or hybridization in-situ (ISH), received at the local laboratory, experienced/certified to determine HER2 expression by means of accurate and validated methods.
  5. Disease progression during or after trastuzumab-based chemotherapy.
  6. Previous chemotherapy on metastatic breast cancer.
  7. Requirements for laboratory parameters determined below:

    Hematology: :

    :

    : ≥ 1500/mm3 (1.5 x 109 cells/L)

    • 100 000/mm3 (100 x 109 cells/L)
    • 9.0 g/dl

    Liver function: Total :

    (AST), Alanine aminotransferase (ALT), Alkalinephosphatase ≤ 1.5 x

    ≤ 2.5 x ULN or ≤ 5.0 х ULN in case of liver and/or bones metastasis Renal function: Serum creatinine or (according to Cocroft-Golt formula): ≤ 1.5 mg/dl > 60 ml/min

  8. Patients must have an status of 0, 1 or 2
  9. Women of (not sterile or in menopause less than 2 years) must be practicing an effective method of during the whole period of the study and 6 months after the last administration of the product. Effective methods of birth control include usage of a condom or diaphragm (barrier method) with spermicide.

Exclusion criteria

Exclusion Criteria:

The patient will be considered ineligible for the study in case she has any criteria listed here below:

  1. cardiovascular diseases:

    • Myocardial infarction within 6 months before screening
    • Unstable angina within 3 months before screening
    • Congestive heart failure Class III or IV according to the (NYHA) criteria
    • Clinically significant ventricular arrhythmia, that have to be treated, including ventricular tachycardia, ventricular fibrillation, history of cardiac arrest
    • > 460 ms () (calculated according to Fredericia formula), or a diagnosis of long QTc syndrome
    • of left ventricle ≤ 50% (EchoCG)
    • Hypotension (systolic arterial blood pressure \< 86 mm of mercury) or bradycardia with a heart rate of \< 50 beats per min., except when caused by medications (e.g. beta-blockers)
    • Uncontrolled arterial hypertension (systolic arterial blood pressure > 170 mm of mercury or diastolic arterial blood pressure > 105 mm of mercury)
    • Troponins I ≥ 0.2 ng/ml
  2. Patients with known cerebral or clinical signs of cerebral metastases.
  3. Patients with severe dyspnea at rest, or those who need additional oxygen therapy in everyday life.
  4. History of to trastuzumab ≥ 3 severity level
  5. History of any toxicity related to trastuzumab administration that resulted in the termination of trastuzumab therapy.
  6. Peripheral neuropathy ≥ II severity level
  7. Bisphosphonate therapy for symptomatic hypercalcemia.
  8. Any chemotherapy, hormonotherapy, radiotherapy, immunotherapy or biological products therapy used for breast cancer treatment within 4 weeks before the first administration of the product.
  9. Previous indication of doxorubicin in maximum cumulated dose > 360 mg/kg2, or its equivalent.
  10. Participation in other clinical studies or administration of other investigational products within 4 weeks before the first administration of the investigational product, or presence of on-going toxicities ≥ II grade according to , related to any prior antitumour therapy (excluding alopecia).
  11. History of other with the exception of cervical carcinoma in situ or skin basal-cell carcinoma, that had undergone surgical removal and treatment within ≥ 5 years before the first administration of the investigational product.
  12. Presence of antibodies to (HIV), or hepatitis С virus (), presence of
  13. Active infection within 4 weeks before the first administration of the investigational product.
  14. Uncontrolled concomitant diseases and conditions, including mental or social, which, in the Investigator's opinion, may prevent the patient from participation in the study.
  15. Drug or alcohol abuse on the moment of screening or in the past, which, in the Investigator's opinion, makes the patient unsuitable for participation in the study.
  16. Pregnant or lactating women, or women who plan to get pregnant during the clinical study
  17. Inability to read or write, unwillingness to understand and comply with the procedures of the study protocol, as well as any other concomitant medical or serious mental conditions, that make the patient unsuitable for participation in the clinical study, limit the validity of receipt or may affect the patient's ability to participate in the study.
Terms in these criteria, in plain language(26)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

HER2

HER2 is a protein, made from the ERBB2 gene, that drives the growth of some cancers. A study may look for a level of the protein, extra copies of the gene, or a particular change in it.

In breast cancer, protein tests are read as HER2-positive, HER2-low or HER2-negative; other cancers use their own rules. Check which test result the study requires.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

CTCAE grade

The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.

1
Mild.
2
Moderate.
3
Severe.
4
Life-threatening.
5
Death due to the event.

“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
6 participants (actual)

Study arms

  • Experimental
    BI-CON-02

    The start dose of BI-CON-02 will be 0,3 mg/kg and it will be possible to increase gradually BI-CON-02 doses up to 0,6 mg/kg; 1,2 mg/kg; 2,4 mg/kg; 3,6 mg/kg and 4,8 mg/kg for subsequent dose cohorts. A possibility to include a new dose cohort in the study will be considered by the Data and Safety Monitoring Committee, basing on the data of BI-CON-02 safety and tolerability, received at the Visit (Week 3, Day1) in the previous dose cohort (3 weeks after - 21st day of therapy).

    Drug: BI-CON-02

Interventions

  • DrugBI-CON-02

    BI-CON-02 prescribed as intravenous infusion once per 3 weeks. Investigational product therapy during 1 year (up to 18 cycles, duration of 21 days each).

06

What researchers measure

Primary outcomes

  1. Incidence of Treatment-Emergent Adverse Events (Safety and Tolerability) Safety and tolerability of multiple doses of Safety and tolerability of multiple doses of BI-CON-02

    The number of patients with treatment-related AEs assessed by CTCAE, abnormal laboratory values and instrumental tests (ECG).

    Time frame: Up to Week 55

  2. Maximum tolerated dose (MTD) or recommended dose (RD) of BI-CON-02

    MTD is defined as maximum dose at which DLT occurs in more than 1 patient of 6

    Time frame: At Week 3 Day 1

Secondary outcomes

  1. Area under the plasma concentration versus time curve (AUC)

    PK analysis of multiple doses of BI-CON-02

    Time frame: Up to 55 weeks

  2. Immunogenetics of BI-CON-02

    Assessment of Antibodies to BI-CON-02 in blood samples

    Time frame: Up to Week 55

  3. Peak Plasma Concentration (Cmax)

    PK analysis of multiple doses of BI-CON-02

    Time frame: Up to 55 weeks

  4. Elimination half-life (T1/2)

    PK analysis of multiple doses of BI-CON-02

    Time frame: Up to 55 weeks

  5. Volume of distribution at steady state (Vss)

    PK analysis of multiple doses of BI-CON-02

    Time frame: Up to 55 weeks

  6. Clearance (CL)

    PK analysis of multiple doses of BI-CON-02

    Time frame: Up to 55 weeks

07

Study locations

6 sites
  • 3. State Medical Preventive Institution "Kirov Region Clinical Oncological Dispensary"
    Kirov, 610021, Russian Federation
  • 5. State Budgetary Public Healthcare Institution "Leningrad Region Oncological Dispensary", department of surgery
    Leningrad Region Settlement Kuz'molovsky, 188663, Russian Federation
  • 2. Moscow State Public Healthcare Institution "Moscow City Oncological Hospital #62 of the Moscow Public Healthcare Department"
    Moscow Region, Krasnogorsk district, settlement Istra, 143423, Russian Federation
  • 1. Federal State Budgetary Institution "Russian Oncological Scientific Center n.a. N.N.Blokhin" of the Russian Academy of Medical Sciences.
    Moscow, 115478, Russian Federation
  • 6. State Budgetary Public Healthcare Institution of the Nizhni Novgorod Region "Nizhni Novgorod Region Oncological Dispensary"
    Nizhni Novgorod, 603081, Russian Federation
  • 4. State Budgetary Educational Institution of Higher Professional Education "Saint-Petersburg State Medical University n.a. academician I.P.Pavlov of the Federal Agency for Public Healthcare and Social Development"
    Saint-Petersburg, 197022, Russian Federation
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Sep 2016 to primary completion in Jun 2017, 9 months.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 8, 2017
First posted
Feb 23, 2017
StartActual
Sep 2016
Primary completionActual
Jun 5, 2017
CompletionActual
Jun 5, 2017
Last update
Jul 16, 2019
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 16, 2019, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03062007
Lead sponsor
Biointegrator LLC
Responsible party
Sponsor
First posted
Feb 23, 2017
Start date
Sep 2016
Primary completion
Jun 5, 2017
Completion
Jun 5, 2017
Last update
Jul 16, 2019

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Feb 2017. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion